Liminal BioSciences Inc.
LMNL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $401 | $643 | $3,317 | $4,904 |
| % Growth | -37.6% | -80.6% | -32.4% | – |
| Cost of Goods Sold | $0 | $0 | $2,033 | $2,763 |
| Gross Profit | $401 | $643 | $1,284 | $2,141 |
| % Margin | 100% | 100% | 38.7% | 43.7% |
| R&D Expenses | $15,298 | $18,347 | $56,826 | $75,114 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $17,866 | $31,928 | $38,552 | $45,283 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$212 | $75 | $79 | $0 |
| Operating Expenses | $33,164 | $50,275 | $95,378 | $120,397 |
| Operating Income | -$32,975 | -$49,557 | -$94,273 | -$210,630 |
| % Margin | -8,223.2% | -7,707.2% | -2,842.1% | -4,295.1% |
| Other Income/Exp. Net | -$525 | $118 | -$28,065 | -$237 |
| Pre-Tax Income | -$29,441 | -$44,945 | -$122,338 | -$234,461 |
| Tax Expense | -$525 | $118 | -$201 | -$237 |
| Net Income | -$28,916 | -$45,063 | -$122,137 | -$234,224 |
| % Margin | -7,211% | -7,008.2% | -3,682.2% | -4,776.2% |
| EPS | -341.8 | -532.66 | -1,443.7 | -2,768.61 |
| % Growth | 35.8% | 63.1% | 47.9% | – |
| EPS Diluted | -9.32 | -14.94 | -49.97 | -145.82 |
| Weighted Avg Shares Out | 85 | 85 | 85 | 85 |
| Weighted Avg Shares Out Dil | 3,104 | 3,016 | 2,444 | 1,606 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $451 | $0 |
| Interest Expense | $1,078 | $6,330 | $8,724 | $14,056 |
| Depreciation & Amortization | $1,120 | $4,344 | $8,447 | $9,906 |
| EBITDA | -$31,855 | -$45,213 | -$105,167 | -$200,724 |
| % Margin | -7,943.9% | -7,031.6% | -3,170.5% | -4,093.1% |